STOCK TITAN

Tecogen Financials

TGEN
Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Tecogen (TGEN) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI TGEN FY2025

External capital is carrying liquidity while higher sales are arriving with weaker economics and little operating self-funding.

FY2024 showed unusual positive cash conversion despite a net loss, but FY2025 flipped the other way: operating cash flow moved from $4.1M to -$9.9M while revenue recovered. The stronger cash balance therefore says more about fresh capital than about a repaired operating model.

The FY2025 sales rebound did not translate into better unit economics: gross margin fell to 36.3% from 43.6%. In the same year, SG&A alone exceeded gross profit, running at $13.5M versus $9.8M, which points to a scale-and-cost mismatch rather than simple top-line softness.

The balance sheet became more liquid on the surface, with cash at $12.4M and a current ratio of 3.1x. But that cushion was externally supplied: financing provided $17.4M, and the higher share count suggests liquidity improved by bringing in capital rather than by generating it internally.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&D Intensity Revenue Progress Burn Trend Balance Sheet 40 / 100
Financial Health Score 40/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Tecogen's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
48
Dilution
50
R&D Intensity
18
Revenue Progress
53
Burn Trend
2
Balance Sheet
71
Altman Z-Score Safe
3.69

Tecogen scores 3.69, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($133.7M) relative to total liabilities ($15.5M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
2/8

Tecogen passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Low Quality
1.20x

For every $1 of reported earnings, Tecogen generates $1.20 in operating cash flow (-$9.9M OCF vs -$8.2M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk
-54.9x

Tecogen earns $-54.9 in operating income for every $1 of interest expense (-$8.2M vs $150K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$27.1M
YoY+19.7%
5Y CAGR-0.9%
10Y CAGR+2.4%

Tecogen generated $27.1M in revenue in fiscal year 2025. This represents an increase of 19.7% from the prior year.

EBITDA
-$7.4M
YoY-85.1%

Tecogen's EBITDA was -$7.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 85.1% from the prior year.

Net Income
-$8.2M
YoY-73.3%

Tecogen reported -$8.2M in net income in fiscal year 2025. This represents a decrease of 73.3% from the prior year.

EPS (Diluted)
$-0.30
YoY-57.9%

Tecogen earned $-0.30 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 57.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow
-$10.3M
YoY-433.6%

Tecogen generated -$10.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 433.6% from the prior year.

Cash & Debt
$12.4M
YoY+130.0%
5Y CAGR+52.8%
10Y CAGR+8.5%

Tecogen held $12.4M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share
N/A
Shares Outstanding
30M
YoY+19.6%
5Y CAGR+3.7%
10Y CAGR+4.9%

Tecogen had 30M shares outstanding in fiscal year 2025. This represents an increase of 19.6% from the prior year.

Margins & Returns

Gross Margin
36.3%
YoY-7.4pp
5Y CAGR-2.0pp
10Y CAGR+0.7pp

Tecogen's gross margin was 36.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 7.4 percentage points from the prior year.

Operating Margin
-30.4%
YoY-10.4pp
5Y CAGR-9.3pp
10Y CAGR-18.1pp

Tecogen's operating margin was -30.4% in fiscal year 2025, reflecting core business profitability. This is down 10.4 percentage points from the prior year.

Net Margin
-30.5%
YoY-9.4pp
5Y CAGR-8.7pp
10Y CAGR-17.8pp

Tecogen's net profit margin was -30.5% in fiscal year 2025, showing the share of revenue converted to profit. This is down 9.4 percentage points from the prior year.

Return on Equity
-38.1%
YoY+8.4pp
5Y CAGR-2.6pp
10Y CAGR-16.9pp

Tecogen's ROE was -38.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 8.4 percentage points from the prior year.

Capital Allocation

R&D Spending
$1.2M
YoY+21.3%
5Y CAGR+8.7%
10Y CAGR+7.0%

Tecogen invested $1.2M in research and development in fiscal year 2025. This represents an increase of 21.3% from the prior year.

Share Buybacks
N/A
Capital Expenditures
$401K
YoY-58.6%
5Y CAGR+46.2%
10Y CAGR+19.1%

Tecogen invested $401K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 58.6% from the prior year.

TGEN Income Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Revenue $6.3M+19.1% $5.3M-26.0% $7.2M-1.5% $7.3M+0.2% $7.3M+19.8% $6.1M+7.9% $5.6M+19.1% $4.7M
Cost of Revenue $3.7M+11.5% $3.4M-32.8% $5.0M+3.5% $4.8M+19.1% $4.1M+21.4% $3.3M+6.1% $3.1M+18.9% $2.6M
Gross Profit $2.6M+32.3% $2.0M-10.4% $2.2M-11.3% $2.5M-23.5% $3.2M+17.8% $2.7M+10.2% $2.5M+19.3% $2.1M
R&D Expenses $364K+18.3% $307K+3.2% $298K+10.9% $269K-8.2% $293K+29.0% $227K-3.0% $234K-5.1% $246K
SG&A Expenses $3.7M-9.1% $4.1M+19.9% $3.4M+10.4% $3.1M+5.6% $2.9M0.0% $2.9M+9.2% $2.7M-7.5% $2.9M
Operating Income -$2.1M+48.4% -$4.1M-97.0% -$2.1M-48.8% -$1.4M-137.6% -$594K+47.7% -$1.1M-30.2% -$873K+40.8% -$1.5M
Interest Expense $34K-11.5% $39K-5.9% $41K+7.8% $38K+18.0% $32K+5.1% $31K+33.7% $23K+28.7% $18K
Income Tax N/A N/A N/A N/A N/A N/A N/A N/A
Net Income -$2.1M+46.9% -$4.0M-87.4% -$2.1M-45.5% -$1.5M-121.9% -$660K+44.4% -$1.2M-27.5% -$930K+39.5% -$1.5M
EPS (Diluted) $-0.07 N/A $-0.07-16.7% $-0.06-100.0% $-0.03 N/A $-0.04+33.3% $-0.06

TGEN Balance Sheet

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Total Assets $34.5M-6.8% $37.0M-10.8% $41.5M+46.2% $28.4M-4.6% $29.7M-4.4% $31.1M+13.1% $27.5M+1.2% $27.2M
Current Assets $26.5M-8.1% $28.9M-10.0% $32.1M+68.5% $19.0M-7.7% $20.6M-6.9% $22.1M+21.9% $18.2M+0.6% $18.1M
Cash & Equivalents $9.3M-24.9% $12.4M-18.5% $15.3M+829.6% $1.6M-59.7% $4.1M-24.8% $5.4M+321.5% $1.3M+52.3% $842K
Inventory $11.4M+4.5% $10.9M+14.6% $9.6M-1.3% $9.7M-2.1% $9.9M+2.6% $9.6M-2.6% $9.9M-2.2% $10.1M
Accounts Receivable $5.1M+18.1% $4.3M-31.2% $6.2M-6.3% $6.6M+13.5% $5.8M-2.9% $6.0M+10.6% $5.4M+1.6% $5.4M
Goodwill $1.2M0.0% $1.2M-46.8% $2.3M0.0% $2.3M0.0% $2.3M0.0% $2.3M-8.5% $2.6M0.0% $2.6M
Total Liabilities $14.9M-3.8% $15.5M-3.9% $16.1M-16.8% $19.4M-4.0% $20.2M-3.6% $21.0M+28.7% $16.3M+8.2% $15.1M
Current Liabilities $8.8M-5.1% $9.3M-21.6% $11.8M-15.4% $14.0M-6.6% $14.9M-11.1% $16.8M+42.0% $11.8M+2.9% $11.5M
Long-Term Debt N/A N/A N/A N/A N/A N/A N/A N/A
Total Equity $19.7M-8.9% $21.6M-15.0% $25.5M+179.8% $9.1M-5.7% $9.6M-5.7% $10.2M-9.5% $11.3M-7.3% $12.2M
Retained Earnings -$58.0M-3.8% -$55.9M-7.7% -$51.9M-4.3% -$49.8M-3.0% -$48.3M-1.4% -$47.6M-2.6% -$46.5M-2.0% -$45.5M

TGEN Cash Flow Statement

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Operating Cash Flow -$3.1M-20.7% -$2.6M+27.7% -$3.6M-36.8% -$2.6M-121.8% -$1.2M-128.1% $4.2M+2115.3% -$207K-31.3% -$158K
Capital Expenditures $46K-2.9% $47K-36.9% $75K-48.4% $146K+10.6% $132K+1.4% $130K-53.9% $282K-37.5% $452K
Free Cash Flow -$3.2M-20.3% -$2.6M+27.9% -$3.6M-32.3% -$2.7M-110.5% -$1.3M-132.3% $4.0M+926.7% -$490K+19.7% -$610K
Investing Cash Flow $50K+172.8% -$69K+6.9% -$74K+52.3% -$156K+5.6% -$165K-38.5% -$119K+63.5% -$327K+34.3% -$497K
Financing Cash Flow -$40K+77.8% -$179K-101.0% $17.2M+5094.6% $332K+259509.4% -$128-100.2% $65K-93.4% $974K+7335.0% -$13K
Dividends Paid N/A N/A N/A N/A N/A N/A N/A N/A
Share Buybacks N/A N/A N/A N/A N/A N/A N/A N/A

TGEN Financial Ratios

Metric Q1'26 Q4'25 Q3'25 Q2'25 Q1'25 Q4'24 Q3'24 Q2'24
Gross Margin 40.9%+4.1pp 36.8%+6.4pp 30.4%-3.4pp 33.8%-10.5pp 44.3%-0.8pp 45.0%+1.0pp 44.1%+0.1pp 44.0%
Operating Margin -33.7%+44.1pp -77.8%-48.6pp -29.3%-9.9pp -19.4%-11.2pp -8.2%+10.5pp -18.7%-3.2pp -15.5%+15.7pp -31.2%
Net Margin -33.5%+41.6pp -75.1%-45.4pp -29.7%-9.6pp -20.1%-11.0pp -9.1%+10.5pp -19.5%-3.0pp -16.5%+16.0pp -32.6%
Return on Equity -10.8%+7.7pp -18.5%-10.1pp -8.4%+7.7pp -16.1%-9.2pp -6.8%+4.8pp -11.6%-3.4pp -8.2%+4.4pp -12.6%
Return on Assets -6.2%+4.7pp -10.8%-5.7pp -5.1%+0.0pp -5.2%-2.9pp -2.2%+1.6pp -3.8%-0.4pp -3.4%+2.3pp -5.7%
Current Ratio 3.02-0.1 3.12+0.4 2.71+1.4 1.36-0.0 1.38+0.1 1.32-0.2 1.53-0.0 1.57
Debt-to-Equity 0.76+0.0 0.72+0.1 0.63-1.5 2.13+0.0 2.09+0.0 2.05+0.6 1.44+0.2 1.24
FCF Margin -49.8%-0.5pp -49.3%+1.3pp -50.6%-13.0pp -37.7%-19.7pp -17.9%-84.6pp 66.6%+75.3pp -8.7%+4.2pp -12.9%

Similar Companies

Frequently Asked Questions

Tecogen (TGEN) reported $27.1M in total revenue for fiscal year 2025. This represents a 19.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Tecogen (TGEN) revenue grew by 19.7% year-over-year, from $22.6M to $27.1M in fiscal year 2025.

No, Tecogen (TGEN) reported a net income of -$8.2M in fiscal year 2025, with a net profit margin of -30.5%.

Tecogen (TGEN) reported diluted earnings per share of $-0.30 for fiscal year 2025. This represents a -57.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Tecogen (TGEN) had EBITDA of -$7.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Tecogen (TGEN) had a gross margin of 36.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Tecogen (TGEN) had an operating margin of -30.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Tecogen (TGEN) had a net profit margin of -30.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Tecogen (TGEN) has a return on equity of -38.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Tecogen (TGEN) generated -$10.3M in free cash flow during fiscal year 2025. This represents a -433.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Tecogen (TGEN) generated -$9.9M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Tecogen (TGEN) had $37.0M in total assets as of fiscal year 2025, including both current and long-term assets.

Tecogen (TGEN) invested $401K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Tecogen (TGEN) invested $1.2M in research and development during fiscal year 2025.

Tecogen (TGEN) had 30M shares outstanding as of fiscal year 2025.

Tecogen (TGEN) had a current ratio of 3.12 as of fiscal year 2025, which is generally considered healthy.

Tecogen (TGEN) had a debt-to-equity ratio of 0.72 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Tecogen (TGEN) had a return on assets of -22.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Tecogen (TGEN) had $12.4M in cash against an annual operating cash burn of $9.9M. This gives an estimated cash runway of approximately 15 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Tecogen (TGEN) has an Altman Z-Score of 3.69, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Tecogen (TGEN) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Tecogen (TGEN) has an earnings quality ratio of 1.20x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Tecogen (TGEN) has an interest coverage ratio of -54.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Tecogen (TGEN) scores 40 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top